Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
作者： C. Parker , S. Nilsson , D. Heinrich , S.I. Helle , J.M. O'Sullivan
关键词:
摘要: efit (median, 14.9 months vs. 11.3 months; hazard ratio, 0.70; 95% CI, 0.58 to 0.83; P<0.001). Assessments of all main secondary efficacy end points also showed a benefit radium-233 as compared with placebo. Radium-223 was associated low myelosuppression rates and fewer adverse events. Conclusions In this study, which terminated for at the prespecified interim analysis, radium-223 improved overall survival. (Funded by Algeta Bayer HealthCare Phar -
warwick.ac.uk
openrepository.com
dissem.in
researchgate.net 参考文章(35)
Paul H. Lange, Robert L. Vessella, Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone. Cancer and Metastasis Reviews. ,vol. 17, pp. 331- 336 ,(1998) , 10.1023/A:1006106209527
Øystein Fodstad, Knut Breistøl, Øyvind S. Bruland, Roy H. Larsen, Gjermund Henriksen, Significant Antitumor Effect from Bone-seeking, α-Particle-emitting 223Ra Demonstrated in an Experimental Skeletal Metastases Model Cancer Research. ,vol. 62, pp. 3120- 3125 ,(2002)
Val J Lewington, Bone-Seeking Radionuclides For Therapy The Journal of Nuclear Medicine. ,vol. 46, ,(2005)
K. K. GORDON LAN, DAVID L. DEMETS, Discrete sequential boundaries for clinical trials Biometrika. ,vol. 70, pp. 659- 663 ,(1983) , 10.1093/BIOMET/70.3.659
William D. Figg, Maha H. Hussain, James L. Gulley, Philip M. Arlen, Jeanny B. Aragon-Ching, Daniel P. Petrylak, Celestia S. Higano, Seth M. Steinberg, Gurkamal S. Chatta, Howard Parnes, John J. Wright, Oliver Sartor, William L. Dahut, A Double-Blind Randomized Crossover Study of Oral Thalidomide Versus Placebo for Androgen Dependent Prostate Cancer Treated With Intermittent Androgen Ablation Journal of Urology. ,vol. 181, pp. 1104- 1113 ,(2009) , 10.1016/J.JURO.2008.11.026
David Cella, Michael B. Nichol, David Eton, Joel B. Nelson, Parvez Mulani, Estimating Clinically Meaningful Changes for the Functional Assessment of Cancer Therapy—Prostate: Results from a Clinical Trial of Patients with Metastatic Hormone-Refractory Prostate Cancer Value in Health. ,vol. 12, pp. 124- 129 ,(2009) , 10.1111/J.1524-4733.2008.00409.X
Silvano Adami, Bisphosphonates in prostate carcinoma Cancer. ,vol. 80, pp. 1674- 1679 ,(1997) , 10.1002/(SICI)1097-0142(19971015)80:8+<1674::AID-CNCR18>3.0.CO;2-X
V. Harris, K. Lloyd, S. Forsey, P. Rogers, M. Roche, C. Parker, A population-based study of prostate cancer chemotherapy. Clinical Oncology. ,vol. 23, pp. 706- 708 ,(2011) , 10.1016/J.CLON.2011.04.014
Peter C. O'Brien, Thomas R. Fleming, A multiple testing procedure for clinical trials. Biometrics. ,vol. 35, pp. 549- 556 ,(1979) , 10.2307/2530245
Cathel Kerr, 223Ra targets skeletal metastases and spares normal tissue Lancet Oncology. ,vol. 3, pp. 453- ,(2002) , 10.1016/S1470-2045(02)00835-5